Skip to content

Clinical application and effect evaluation of fullerene hydrogel for topical application in the prevention of acute radiation dermatitis

Clinical application and effect evaluation of fullerene hydrogel for topical application in the prevention of acute radiation dermatitis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102198
Enrollment
Unknown
Registered
2025-05-11
Start date
2025-05-11
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute radiation dermatitis

Interventions

Experimental group:fullerene hydrogel
Control group:Silymarin gel

Sponsors

The Second Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) Age > 18 years and = 70; 5) Planning to receive at least 4 weeks of radiation therapy; 6) Pre-radiotherapy peripheral white blood cell count >= 4×10?/L, hemoglobin >= 90 g/L, platelets >= 80×10?/L; 7) Non-allergic; 8) Patients are alert and able to communicate effectively with researchers; 9) Voluntarily participate in this study after providing informed consent.

Exclusion criteria

Exclusion criteria: 1) Those who are obviously restless and have mental symptoms; 2) Those who have other skin diseases concurrently in the radiation field; 3) Those with organ dysfunction, such as severe heart failure, renal failure, etc. Exclusion criteria.

Design outcomes

Primary

MeasureTime frame
Incidence of acute radiation dermatitis at all levels;Minimum cumulative dose for all levels of acute radiation dermatitis;

Secondary

MeasureTime frame
pain;Skindex-16;

Countries

China

Contacts

Public ContactGuo Jinli

The Second Hospital of Shanxi Medical University

gjlgbd@126.com+86 135 4639 5590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026